Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 11/20 | 0.69 |
| ▸ | P2RX1 | P51575 | 13/20 | 0.65 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MYLK | Q15746 | 1/20 | 0.50 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468872 | 0.89 | P2RX1 (0.66) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL5464212 | 0.85 | P2RX1 (0.60) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL14363380 | 0.82 | TMPRSS4 (0.79) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL134080 | 0.81 | TMPRSS4 (0.77) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL14885878 | 0.81 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL5455080 | 0.79 | RAB9A (0.59) | KMT2A | |
| SCHEMBL130066 | 0.79 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL5462330 | 0.79 | PNLIP (0.62) | MEN1KMT2A | |
| SCHEMBL5461743 | 0.78 | KDM4E (0.54) | TMPRSS4P2RX1MEN1KMT2A | |
| SCHEMBL5461688 | 0.77 | HTT (0.53) | P2RX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | TMPRSS4 342/4885P2RX1 4478/4885P2RX4 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.